Studying Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia Previously Enrolled on Clinical Trial POG-9421
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01035307|
Recruitment Status : Completed
First Posted : December 18, 2009
Last Update Posted : May 18, 2016
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is looking at biomarkers in tissue samples from young patients with acute myeloid leukemia previously enrolled on clinical trial POG-9421.
|Condition or disease||Intervention/treatment|
|Leukemia||Genetic: gene expression analysis Genetic: microarray analysis Genetic: proteomic profiling Other: laboratory biomarker analysis|
- To profile basal and potentiated phospho-protein networks (PPPNs) using tissue samples from pediatric patients with de novo acute myeloid leukemia (AML) previously enrolled on clinical trial POG-9421.
- To classify AML-based signal transduction mechanisms.
- To correlate profiles of basal and PPPNs with specific molecular lesions (e.g., FLT3-ITD, NPM, WT1, c-kit, CEPBα, PASGΔ75, and karyotype) and profiles of gene expression in tumor tissue samples.
OUTLINE: Banked tissue samples are collected for laboratory studies, including phospho-protein signaling and gene expression profiling studies.
|Study Type :||Observational|
|Estimated Enrollment :||90 participants|
|Official Title:||Genomic and Proteomic Profiling of Childhood AML|
|Study Start Date :||October 2009|
|Actual Primary Completion Date :||May 2016|
|Genomic and Proteomic Profiling||Genetic: gene expression analysis Genetic: microarray analysis Genetic: proteomic profiling Other: laboratory biomarker analysis|
- Profiling of basal and potentiated phospho-protein networks (PPPNs) using tissue samples
- Classification of AML-based signal transduction mechanisms
- Correlation of basal and PPPN profiles with specific molecular lesions (e.g., FLT3-ITD, NPM, WT1, c-kit, CEPBα, PASGΔ75, and karyotype) and gene expression profiles.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01035307
|Principal Investigator:||Norman J. Lacayo, MD||Stanford University|